Effects of Lagenbone on Bone Mineral Density
Effects of Lagenbone on Improvements in Bone Mineral Density - A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Whittier, California, United States, 90604
- Southern California University of Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of osteoporosis
- Able to read and understand English
- Willing to receive routine DEXA scans and comply with supplement schedule
Exclusion Criteria:
- Pregnant, lactating, or having gestational diabetes
- Diagnosed with comorbid conditions that they are taking medication for e.g. Acid reflux, Hashimoto's/Grave's Disease, Endometriosis, prostate, breast, uterine cancer, kidney disease, fibroids, psychological disorders
- Use of any medication known to interfere with bone mineral density
- Are taking any new medications/supplements/treatments/therapeutic exercise within the last two months for osteoporosis or bone density
- Involved in health-related litigation, claims
- Missing baseline visits
- Vegan or vegetarian
- Diagnosed with Alzheimer's or demonstrating onset of dementia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lagenbone
Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
|
Traditional Chinese medicine herbal formula
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dual-energy x-ray absorptiometry (DXA)DEXA Scan
Time Frame: 15 months
|
Dual-energy x-ray absorptiometry (DXA) or bone densitometry or Bone Density Scan
|
15 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short Osteoporosis Quality of Life Questionnaire (ECOS16)
Time Frame: 15 months
|
Short Osteoporosis Quality of Life Questionnaire
|
15 months
|
|
36-item Short form survey (SF36)
Time Frame: 15 months
|
36-item Short form survey
|
15 months
|
|
Osteoporotic Quality of Life Questionnaire (OQLQ10)
Time Frame: 15 months
|
Osteoporotic Quality of Life Questionnaire
|
15 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SUNT001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
NCT03710889CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis Vertebral
-
NCT03512262CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae
-
NCT06938152RecruitingOsteoporosis | Osteoporosis Postmenopausal
-
NCT02604836Completed
-
NCT02598934Completed
-
NCT03026660CompletedPostmenopausal Osteoporosis | Osteoporosis, Osteopenia
-
NCT05571514Recruiting
-
NCT02347865CompletedPost Menopausal Osteoporosis
-
NCT00377234CompletedPost Menopausal Osteoporosis
-
NCT00048074Completed